Source - LSE Regulatory
RNS Number : 4333J
e-Therapeutics plc
27 April 2022
 

e-therapeutics plc

("e-therapeutics" or "the Company")

 

Notification of Full Year Results Date

 

Oxford, UK, 27 April 2022 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, will announce its full year audited results for the year ended 31 January 2022 on Wednesday 4 May 2022.

 

Enquiries:

 

e-therapeutics plc


Ali Mortazavi, CEO                                        

James Chandler, VP IR & Strategic Communications

Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk





 

SP Angel Corporate Finance LLP

 

 

Tel: +44(0)20 3470 0470

Nominated Adviser and Broker

 


Matthew Johnson/Caroline Rowe (Corporate Finance)

 


Vadim Alexandre/Rob Rees (Corporate Broking)




 

About e-therapeutics plc

e-therapeutics plc is a UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity. 

 

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology. 

 

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORZZGZDVVKGZZM
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.